Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

/p>

"This year continues to be very eventful for DOR," stated Christopher J. Schaber, PhD, President and CEO of DOR. "With our new partnership with Sigma-Tau, we are working diligently towards the initiation of our confirmatory Phase 3 clinical trial of orBec((R)) in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. Once the clinical trial is initiated, we expect to receive a $1 million milestone payment from Sigma-Tau in accordance with our collaboration agreement."

DOR's Recent Highlights:

On August 4, 2009, DOR announced that the Office of Orphan Products Development of the FDA granted Orphan Drug Designation to Oral BDP (beclomethasone 17,21-dipropionate, or orBec(R)) for the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host disease.

On July 8, 2009, DOR announced that it received a European patent addressing its Lipid Polymer Micelle (LPM(TM)) technology for the improved oral delivery of drugs.

On July 7, DOR announced the appointment of Christopher P. Schnittker, CPA, as its new Vice President of Administration and Controller.

On June 29, 2009, DOR announced the publication in Bone Marrow Transplantation of orBec(R) clinical pulmonary data by investigators at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

On June 9, 2009, DOR announced that it received European Medicines Evaluation Agency (EMEA) agreement on the design of its confirmatory Phase 3 clinical trial of orBec(R) in acute GI GVHD.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec((R)) (oral beclomethasone dipropionate or
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Guggenheim Securities, the investment banking and capital markets ... veteran equity analyst Charles "Tony" Butler as a managing ... on the biotech/biopharma sector. " Tony Butler ... a broad network of relationships in his industry," said ... of Equities at Guggenheim Securities. "His insights will further ...
(Date:8/27/2014)... 27, 2014  ARCH Venture Partners, one of ... the development of seed and early-stage advanced technology ... closed with more than $400 million in subscriptions. ... subscription target by more than $150 million. ... strength and potential of our approach to finding ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/26/2014)... -- NeuroSigma, Inc., a Los Angeles -based ... announced that it has filed a registration statement on ... relating to a proposed initial public offering of its ... and the price range for the proposed offering have ... act as the book-running manager for the proposed offering, ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... , , NEW YORK, Aug. 13 ... the second quarter ended June 30, 2009. , , Revenues ... in 2008. Net loss for the second quarter of 2009 was $103,330, ... Basic net loss per share for the second quarter of 2009 was $0.01, ...
... , , MANHATTAN, ... around the world hundreds of millions of dollars each year. , ... Hesse and Bob Rowland have been working to create new vaccines ... and its associated diseases continue to emerge around the world," Hesse ...
... FORT LAUDERDALE, Fla., Aug. 13 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials, today announced that it ... Organization (CRO) to provide eClinical solutions for a pivotal Phase ... serve to establish the safety and efficacy of investigational new ...
Cached Biology Technology:Cadus Reports Second Quarter 2009 Results 2Cadus Reports Second Quarter 2009 Results 3Cadus Reports Second Quarter 2009 Results 4Cadus Reports Second Quarter 2009 Results 5K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 2K-State's Biosecurity Research Institute Gives Researchers the Tools Needed to Study Diseases That Cost Pig Producers Hundreds of Millions of Dollars Each Year 3Leading European Contract Research Organization Selects OmniComm to Provide eClinical Solutions for Important Phase III Study 2
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have largely succeeded in sidelining the use of ... its potential contributions to Americans, health conditions. But ... best way to assuage the nation,s insatiable sweet ... & Engineering News (C&EN), the weekly news ... the article, Stephen Ritter, a senior correspondent at ...
(Date:8/27/2014)... can be weaned later with no negative effects on ... at the University,s Roseworthy campus, published in the journal ... for pig producers. It allows improvements in piglet health ... usually start their oestrous cycles again during lactation, only ... says Ms Alice Weaver, PhD candidate with the School ...
Breaking Biology News(10 mins):New study throws into question long-held belief about depression 2Piglet weaning age no bar to litter frequency 2
... identify new anti-cancer, anti-infection response control mechanism , ... de recherches cliniques de Montréal (IRCM), and his ... the prestigious journal Nature Immunology of Nature Publishing ... treatment of cancers and infectious diseases. Current treatments ...
... to clone human embryos from eggs that have been ... easier for scientists to create embryonic stem cell lines ... and sperm for infertile couples, the 21st annual conference ... heard today (Monday 20 June). , Until now, scientists ...
... the structure of a crucial human immune system molecule ... an upcoming issue of the journal Science, the protein ... 23 leucine-rich repeats (LRRs). , The structure reveals details ... essential step toward fully understanding the critical role this ...
Cached Biology News:Major breakthrough in the treatment of cancers and infectious diseases 2Scientists succeed in cloning human embryos from eggs matured in the lab 2Scientists succeed in cloning human embryos from eggs matured in the lab 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4